HER2/NEU GENE EXPRESSION PRODUCTS EVALUATED WITH SUPERPARAMAGNETIC, GENETICALLY ENGINEERED ANTIBODIES

Area of Science:

• Oncology
• Biotechnology
• Medical Imaging

Background:

• HER2/neu protooncogene amplification and overexpression are common in breast and ovarian cancers, correlating with malignancy.
• HER2/neu receptor expression drives cell proliferation and is a key target for antibody-based therapies.
• Accurate assessment of HER2/neu levels and distribution is crucial for effective cancer treatment planning.

Purpose of the Study:

• To engineer molecular probes for in vivo detection of HER2/neu gene expression levels.
• To visualize the anatomical distribution of HER2/neu expression using Magnetic Resonance Imaging (MRI).
• To establish a diagnostic tool for receptor-targeted cancer therapies.

Main Methods:

• Genetic engineering of superparamagnetic single chain variable fragment (scFv) antibodies targeting HER2/neu receptors.
• Evaluation of probe specificity and affinity using EDXSI.
• Assessment of probe-induced relaxivity changes using Nuclear Magnetic Resonance (NMR).
• Application of probes with MRI for in vivo imaging.

Main Results:

• Engineered scFv antibodies demonstrated high specificity and affinity for HER2/neu receptors.
• Probes induced significant changes in relaxivity, detectable by NMR.
• Successful proof-of-concept for in vivo HER2/neu detection using MRI.

Conclusions:

• Superparamagnetic scFvs are effective molecular probes for quantifying HER2/neu expression in vivo.
• NMR and MRI can be utilized for diagnostic evaluation of HER2/neu levels.
• This approach facilitates planning of HER2/neu receptor-targeted therapies.